Crescendo Bioscience Highlights New Studies With Vectra(R) DA That Will Be Presented at the American College of Rheumatology ...
22 October 2015 - 10:05PM
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics,
Inc. (NASDAQ:MYGN), today announced that new data on Vectra DA will
be presented at the American College of Rheumatology/Association of
Rheumatology Health Professionals (ACR/ARHP) meeting being held
Nov. 7-11, 2015 in San Francisco, Calif.
A list of the highlighted Crescendo Bioscience presentations at
ACR (#ACR15) follows:
Poster Presentations
- Title: The multi-biomarker disease activity
score in methotrexate incomplete responders predicts clinical
responses to non-biological vs. biological therapy in early RA.
Authors: K. Hambardzumyan, R. Bolce, S.
Saevarsdottir, K. Forslind, J.A. Karlsson and R.F. van
Vollenhoven. Date: Sunday, Nov. 8, 2015:
9:00-11:00 a.m. PT. Abstract: 618.
- Title: Multi-biomarker disease activity score
as a predictor of flare in patients with rheumatoid arthritis who
stop TNF-alpha-inhibitor therapy. Authors: F.
Lamers-Karnebeek, M. Ghiti Moghadam, H.E. Vonkeman, J. Tekstra, A.
Schilder, H. Visser, P.M. ten Klooster, E.H. Sasso, D. Chernoff, W.
Lems, D. van Schaardenburg, R. Landewé, L. Van Albada, T.R.D.J.
Radstake, P. van Riel, M.A.F.J. van de Laar and T. Jansen.
Date: Tuesday, Nov. 10, 2015: 9:00-11:00 a.m. PT.
Abstract: 2594.
- Title: Prediction of disease relapses by
multi-biomarker disease test activity in rheumatoid arthritis
patients tapering DMARD treatment. Authors: J.
Rech, A.J. Hueber, M. Englbrecht, S. Finzel, J. Haschka, B. Manger,
A. Kleyer, M. Reiser, H-P Tony, S. Kleinert, M. Feuchtenberger, M.
Fleck, K. Manger, W. Ochs, M. Schmitt-Haendle, J. Wendler, F.
Schuch, M. Ronneberger, H-M Lorenz, H. Nüßlein, R. Alten, J.
Fogagnolo Cobra, J.C. Henes, K. Krüger and G.A. Schett.
Date: Tuesday, Nov. 10, 2015: 9:00-11:00 a.m. PT.
Abstract: 2584.
For more information about these presentations, including a
complete list of abstracts and presentations, please visit the ACR
website at http://acrannualmeeting.org/abstracts/.
About Vectra® DA
Vectra DA is the only multi-biomarker blood test for rheumatoid
arthritis (RA) disease activity that integrates the concentrations
of 12 serum proteins associated with RA disease activity into a
single objective score, on a scale of 1 to 100, to help physicians
make more informed treatment decisions. Vectra DA testing is
performed at the Crescendo Bioscience state-of-the-art CLIA
(Clinical Laboratory Improvement Amendments) facility. Test results
are reported to the physician 5 to 7 days from shipping of the
specimen to Crescendo Bioscience. Physicians can receive test
results via standard mail, by fax or via the private web portal,
VectraView. For more information on Vectra DA, please visit:
www.Vectra-DA.com.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad
Genetics, Inc., is a molecular diagnostics company dedicated to
developing and commercializing quantitative blood tests for
rheumatoid arthritis (RA) and other autoimmune diseases, located in
South San Francisco, Calif. Crescendo Bioscience develops
quantitative, objective, reproducible blood tests to provide
rheumatologists with deeper clinical insight to help enable more
effective management of patients with autoimmune and inflammatory
diseases. For more information, please visit the company's
website at: www.CrescendoBio.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where
molecular diagnostics can significantly improve patient care and
lower healthcare costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the
introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to the Vectra DA data to
be presented at the 2015 American College of Rheumatology
(ACR) Annual Meeting, November 7-11, 2015, in San Francisco,
Calif.; and the Company's strategic directives under the caption
"About Myriad Genetics." These "forward-looking statements"
are based on management's current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers'
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2015, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024